Vigil Neuroscience is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/18/21 | $90,000,000 | Series B |
Atlas Venture Cormorant Asset Management Deep Track Capital Hatteras Venture Partners Invus Logos Capital Northpond Ventures OrbiMed Advisors Pivotal bioVenture Partners Rock Springs Capital Surveyor Capital Vida Ventures  | undisclosed |
